New hope for preventing dangerous pregnancy complication
NCT ID NCT07361679
Summary
This study aims to see if adding a blood-thinning medication (low molecular weight heparin) to standard low-dose aspirin is more effective at preventing preeclampsia than aspirin alone in pregnant women identified as high-risk. It will involve 100 women who will start treatment before 16 weeks of pregnancy and continue until 36 weeks. Researchers will track who develops preeclampsia and related complications to determine which approach works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Department of Obstetrics and Gynecology, Alexandra Hospital
RECRUITINGAthens, Attica, 11528, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.